1Department
of Circulation and Medical Imaging, Norwegian University of Science and
Technology (NTNU), Trondheim, Norway; 2Departments of Radiology,
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 3Departments
of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands; 4Departments of Cell Biology, Radboud University
Nijmegen Medical Centre, Nijmegen, Netherlands; 5Department of
Circulation and Medical Imaging, Norwegian University of Science and
Technology, Trondheim, Norway
Glioma patients harboring the isocitrate dehydrogenase 1 (IDH1) mutation have a better prognosis than those without. As IDH1 regulates several pathways towards lipid synthesis we hypothesized that IDH1 mutant tumors can be identified by 31P-MRS. Localized 31P MR spectra were acquired from four distinct human glioma xenografts including an IDH1mutated model. The IDH1 mutated xenografts were distinguishable from the IDH1wt tumors by significantly higher PC/PE and GPC/GPE ratios. This 31P-spectral profile of the IDH1-mutated model was also observed in extracted tumor tissues and in cell lines expressing mutated-IDH1, and finally in intact human surgical biopsies harboring IDH1-mutation.